A meta-analysis of large randomized controlled trials examining the association between incretin-based therapies and AP revealed an 82% (95% CI, 1.17–2.82) higher likelihood of developing AP when using these drugs compared to conventional therapy (Roshanov and Dennis, 2015). This evidence concerns the gene GCG and alkaline phosphatase measurement.